Results 41 to 50 of about 6,099,308 (408)
M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes. [PDF]
, 2017 Acute injury in the setting of liver fibrosis is an interesting and still unsettled issue. Most recently, several prominent studies have indicated the favourable effects of liver fibrosis against acute insults.
Bai, Li +13 more
core +2 more sources
Gut and Liver, 2019 Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common cancer in men in Korea, where the prevalence of chronic hepatitis B infection is high in middle-aged and elderly patients.
KLCA Korean Liver Cancer Association +1 more
doaj +1 more source
World Journal of Surgical Oncology, 2021 Background Thrombocytopenia was reported both detrimental and advantageous to hepatocellular carcinoma (HCC). However, there is little evidence showing clearly the clinical value of preoperative thrombocytopenia on the surgical outcome of patients with ...
Wei Peng +4 more
doaj +1 more source
Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog [PDF]
, 2009 Alcohol synergistically enhances the progression of liver disease and the risk for liver cancer caused by hepatitis C virus (HCV). However, the molecular mechanism of this synergy remains unclear.
Asahina, Kinji +13 more
core +2 more sources
Molecular Oncology, 2022 We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC).
Gui‐Qi Zhu +18 more
doaj +1 more source
The evaluation of liver fibrosis regression in chronic hepatitis C patients after the treatment with direct-acting antiviral agents – A review of the literature [PDF]
, 2019 The second-generation of direct-acting antiviral agents are the current treatment for chronic viral hepatitis C infection. To evaluate the regression of liver fibrosis in patients receiving this therapy, liver biopsy remains the most accurate method, but
Alexescu, Teodora G +12 more
core +3 more sources
Bile Acid Receptor Therapeutics Effects on Chronic Liver Diseases [PDF]
, 2020 In the past ten years, our understanding of the importance of bile acids has expanded from fat absorption and glucose/lipid/energy homeostasis into potential therapeutic targets for amelioration of chronic cholestatic liver diseases.
Alpini, Gianfranco +4 more
core +1 more source
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Hepatology, 2019 Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world.
Z. Younossi +10 more
semanticscholar +1 more source
Scientific Reports, 2017 Portal hypertension (PH) is a major cause of morbidity and mortality in chronic liver disease. Infection and inflammation play a role in potentiating PH and pro-inflammatory cytokines, including TNF, are associated with severity of PH.
V. Balasubramanian +6 more
doaj +1 more source
Signal Transduction and Targeted Therapy, 2023 Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC.
Guo-Ming Shi +22 more
doaj +1 more source